Increased number of monocytes and plasma levels of MCP‐1 and YKL‐40 in first‐episode psychosis
Objective Accumulating evidence implicates immune activation in the development of schizophrenia. Here, monocyte numbers, monocyte chemoattractant protein‐1 (MCP‐1) and chitinase‐3‐like protein 1 (YKL‐40) were investigated in plasma and cerebrospinal fluid (CSF) in first‐episode psychosis (FEP) pati...
Gespeichert in:
| Veröffentlicht in: | Acta psychiatrica Scandinavica 2018-11, Vol.138 (5), p.432-440 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 440 |
|---|---|
| container_issue | 5 |
| container_start_page | 432 |
| container_title | Acta psychiatrica Scandinavica |
| container_volume | 138 |
| creator | Orhan, F. Schwieler, L. Fatouros‐Bergman, H. Malmqvist, A. Cervenka, S. Collste, K. Flyckt, L. Farde, L. Sellgren, C. M. Piehl, F. Engberg, G. Erhardt, S. Hedberg, Mikael Victorsson, Pauliina |
| description | Objective
Accumulating evidence implicates immune activation in the development of schizophrenia. Here, monocyte numbers, monocyte chemoattractant protein‐1 (MCP‐1) and chitinase‐3‐like protein 1 (YKL‐40) were investigated in plasma and cerebrospinal fluid (CSF) in first‐episode psychosis (FEP) patients.
Method
CSF and blood were sampled from 42 first‐episode psychosis (FEP) patients and 22 healthy controls. The levels of YKL‐40 and MCP‐1 were measured using electrochemiluminescence assay, and blood monocytes were counted using an XN‐9000‐hematology analyzer.
Results
We found higher plasma levels of MCP‐1 and YKL‐40 in FEP patients compared with healthy controls, a condition that was unrelated to antipsychotic and/or anxiolytic medication. This was combined with an increased number of blood monocytes and a borderline significant increase in YKL‐40 levels in the CSF of tobacco‐free FEP patients. Plasma or CSF chemokines or blood monocytes did not correlate with the severity of symptoms or the level of functioning.
Conclusion
These data demonstrate activation of monocytes in FEP and strengthens the idea of an immune dysfunction of psychotic disorders. Further studies are required to perceive a role of YKL‐40 and MCP‐1 in the initiation and progression of schizophrenia. |
| doi_str_mv | 10.1111/acps.12944 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_486131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2125490335</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4324-2e6daa5404e2a5ff623c6f1a254438a346a523887285e304d1d7f78bfad5da8b3</originalsourceid><addsrcrecordid>eNp9kcmO1DAQhi0EYpqBCw-ALHEZITJ4S-I-tpptRCNGYhGcLCcug4ckDq4Oo77xCDwjT4J70swBCepS26dfVfoJuc_ZKc_xxLYjnnKxVOoGWfCKsYIpVd8kC8YYL6ol-3hE7iBe5LbkTN8mR5JxKTQTC-LOhjaBRXB0mPoGEo2e9nGI7W4LSO3g6NhZ7C3t4Dt0uF-_Xp__-vGTXy0_vdrkWjEaBupDwm3uYAwYHdARd-2XiAHvklvedgj3DvmYvH_-7N36ZbF58-JsvdoUrZJCFQIqZ22pmAJhS-8rIdvKcytKpaS2UlW2FFLrWugSJFOOu9rXuvHWlc7qRh6TYtbFSxinxowp9DbtTLTBHEZfcwVG6YpLnvnH_-Sfhg8rE9NnM01GKVaLPX4y42OK3ybArekDttB1doA4oRFsyTXPJ8qMPvwLvYhTGvLzRvD8z5JJWWbq0Uy1KSIm8NcXcGb21pq9tebK2gw_OEhOTQ_uGv3jZQb4DFyGDnb_kTKr9fnbWfQ3VG2v_A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2125490335</pqid></control><display><type>article</type><title>Increased number of monocytes and plasma levels of MCP‐1 and YKL‐40 in first‐episode psychosis</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Orhan, F. ; Schwieler, L. ; Fatouros‐Bergman, H. ; Malmqvist, A. ; Cervenka, S. ; Collste, K. ; Flyckt, L. ; Farde, L. ; Sellgren, C. M. ; Piehl, F. ; Engberg, G. ; Erhardt, S. ; Hedberg, Mikael ; Victorsson, Pauliina</creator><creatorcontrib>Orhan, F. ; Schwieler, L. ; Fatouros‐Bergman, H. ; Malmqvist, A. ; Cervenka, S. ; Collste, K. ; Flyckt, L. ; Farde, L. ; Sellgren, C. M. ; Piehl, F. ; Engberg, G. ; Erhardt, S. ; Hedberg, Mikael ; Victorsson, Pauliina ; Karolinska Schizophrenia Project (KaSP) Consortium</creatorcontrib><description>Objective
Accumulating evidence implicates immune activation in the development of schizophrenia. Here, monocyte numbers, monocyte chemoattractant protein‐1 (MCP‐1) and chitinase‐3‐like protein 1 (YKL‐40) were investigated in plasma and cerebrospinal fluid (CSF) in first‐episode psychosis (FEP) patients.
Method
CSF and blood were sampled from 42 first‐episode psychosis (FEP) patients and 22 healthy controls. The levels of YKL‐40 and MCP‐1 were measured using electrochemiluminescence assay, and blood monocytes were counted using an XN‐9000‐hematology analyzer.
Results
We found higher plasma levels of MCP‐1 and YKL‐40 in FEP patients compared with healthy controls, a condition that was unrelated to antipsychotic and/or anxiolytic medication. This was combined with an increased number of blood monocytes and a borderline significant increase in YKL‐40 levels in the CSF of tobacco‐free FEP patients. Plasma or CSF chemokines or blood monocytes did not correlate with the severity of symptoms or the level of functioning.
Conclusion
These data demonstrate activation of monocytes in FEP and strengthens the idea of an immune dysfunction of psychotic disorders. Further studies are required to perceive a role of YKL‐40 and MCP‐1 in the initiation and progression of schizophrenia.</description><identifier>ISSN: 0001-690X</identifier><identifier>ISSN: 1600-0447</identifier><identifier>EISSN: 1600-0447</identifier><identifier>DOI: 10.1111/acps.12944</identifier><identifier>PMID: 30132802</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Antipsychotics ; Blood ; Cell activation ; Cerebrospinal fluid ; Chemokines ; Chitinase ; first-episode psychosis ; Hematology ; Immune response ; Mental disorders ; Monocyte chemoattractant protein ; Monocytes ; neuroimmunology ; Plasma ; Plasma levels ; Psychosis ; Schizophrenia ; Tobacco</subject><ispartof>Acta psychiatrica Scandinavica, 2018-11, Vol.138 (5), p.432-440</ispartof><rights>2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2018 John Wiley & Sons A/S, Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4324-2e6daa5404e2a5ff623c6f1a254438a346a523887285e304d1d7f78bfad5da8b3</citedby><cites>FETCH-LOGICAL-c4324-2e6daa5404e2a5ff623c6f1a254438a346a523887285e304d1d7f78bfad5da8b3</cites><orcidid>0000-0003-1659-5232</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Facps.12944$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Facps.12944$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30132802$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-440721$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:139504946$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Orhan, F.</creatorcontrib><creatorcontrib>Schwieler, L.</creatorcontrib><creatorcontrib>Fatouros‐Bergman, H.</creatorcontrib><creatorcontrib>Malmqvist, A.</creatorcontrib><creatorcontrib>Cervenka, S.</creatorcontrib><creatorcontrib>Collste, K.</creatorcontrib><creatorcontrib>Flyckt, L.</creatorcontrib><creatorcontrib>Farde, L.</creatorcontrib><creatorcontrib>Sellgren, C. M.</creatorcontrib><creatorcontrib>Piehl, F.</creatorcontrib><creatorcontrib>Engberg, G.</creatorcontrib><creatorcontrib>Erhardt, S.</creatorcontrib><creatorcontrib>Hedberg, Mikael</creatorcontrib><creatorcontrib>Victorsson, Pauliina</creatorcontrib><creatorcontrib>Karolinska Schizophrenia Project (KaSP) Consortium</creatorcontrib><title>Increased number of monocytes and plasma levels of MCP‐1 and YKL‐40 in first‐episode psychosis</title><title>Acta psychiatrica Scandinavica</title><addtitle>Acta Psychiatr Scand</addtitle><description>Objective
Accumulating evidence implicates immune activation in the development of schizophrenia. Here, monocyte numbers, monocyte chemoattractant protein‐1 (MCP‐1) and chitinase‐3‐like protein 1 (YKL‐40) were investigated in plasma and cerebrospinal fluid (CSF) in first‐episode psychosis (FEP) patients.
Method
CSF and blood were sampled from 42 first‐episode psychosis (FEP) patients and 22 healthy controls. The levels of YKL‐40 and MCP‐1 were measured using electrochemiluminescence assay, and blood monocytes were counted using an XN‐9000‐hematology analyzer.
Results
We found higher plasma levels of MCP‐1 and YKL‐40 in FEP patients compared with healthy controls, a condition that was unrelated to antipsychotic and/or anxiolytic medication. This was combined with an increased number of blood monocytes and a borderline significant increase in YKL‐40 levels in the CSF of tobacco‐free FEP patients. Plasma or CSF chemokines or blood monocytes did not correlate with the severity of symptoms or the level of functioning.
Conclusion
These data demonstrate activation of monocytes in FEP and strengthens the idea of an immune dysfunction of psychotic disorders. Further studies are required to perceive a role of YKL‐40 and MCP‐1 in the initiation and progression of schizophrenia.</description><subject>Antipsychotics</subject><subject>Blood</subject><subject>Cell activation</subject><subject>Cerebrospinal fluid</subject><subject>Chemokines</subject><subject>Chitinase</subject><subject>first-episode psychosis</subject><subject>Hematology</subject><subject>Immune response</subject><subject>Mental disorders</subject><subject>Monocyte chemoattractant protein</subject><subject>Monocytes</subject><subject>neuroimmunology</subject><subject>Plasma</subject><subject>Plasma levels</subject><subject>Psychosis</subject><subject>Schizophrenia</subject><subject>Tobacco</subject><issn>0001-690X</issn><issn>1600-0447</issn><issn>1600-0447</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kcmO1DAQhi0EYpqBCw-ALHEZITJ4S-I-tpptRCNGYhGcLCcug4ckDq4Oo77xCDwjT4J70swBCepS26dfVfoJuc_ZKc_xxLYjnnKxVOoGWfCKsYIpVd8kC8YYL6ol-3hE7iBe5LbkTN8mR5JxKTQTC-LOhjaBRXB0mPoGEo2e9nGI7W4LSO3g6NhZ7C3t4Dt0uF-_Xp__-vGTXy0_vdrkWjEaBupDwm3uYAwYHdARd-2XiAHvklvedgj3DvmYvH_-7N36ZbF58-JsvdoUrZJCFQIqZ22pmAJhS-8rIdvKcytKpaS2UlW2FFLrWugSJFOOu9rXuvHWlc7qRh6TYtbFSxinxowp9DbtTLTBHEZfcwVG6YpLnvnH_-Sfhg8rE9NnM01GKVaLPX4y42OK3ybArekDttB1doA4oRFsyTXPJ8qMPvwLvYhTGvLzRvD8z5JJWWbq0Uy1KSIm8NcXcGb21pq9tebK2gw_OEhOTQ_uGv3jZQb4DFyGDnb_kTKr9fnbWfQ3VG2v_A</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Orhan, F.</creator><creator>Schwieler, L.</creator><creator>Fatouros‐Bergman, H.</creator><creator>Malmqvist, A.</creator><creator>Cervenka, S.</creator><creator>Collste, K.</creator><creator>Flyckt, L.</creator><creator>Farde, L.</creator><creator>Sellgren, C. M.</creator><creator>Piehl, F.</creator><creator>Engberg, G.</creator><creator>Erhardt, S.</creator><creator>Hedberg, Mikael</creator><creator>Victorsson, Pauliina</creator><general>Blackwell Publishing Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DF2</scope><orcidid>https://orcid.org/0000-0003-1659-5232</orcidid></search><sort><creationdate>201811</creationdate><title>Increased number of monocytes and plasma levels of MCP‐1 and YKL‐40 in first‐episode psychosis</title><author>Orhan, F. ; Schwieler, L. ; Fatouros‐Bergman, H. ; Malmqvist, A. ; Cervenka, S. ; Collste, K. ; Flyckt, L. ; Farde, L. ; Sellgren, C. M. ; Piehl, F. ; Engberg, G. ; Erhardt, S. ; Hedberg, Mikael ; Victorsson, Pauliina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4324-2e6daa5404e2a5ff623c6f1a254438a346a523887285e304d1d7f78bfad5da8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antipsychotics</topic><topic>Blood</topic><topic>Cell activation</topic><topic>Cerebrospinal fluid</topic><topic>Chemokines</topic><topic>Chitinase</topic><topic>first-episode psychosis</topic><topic>Hematology</topic><topic>Immune response</topic><topic>Mental disorders</topic><topic>Monocyte chemoattractant protein</topic><topic>Monocytes</topic><topic>neuroimmunology</topic><topic>Plasma</topic><topic>Plasma levels</topic><topic>Psychosis</topic><topic>Schizophrenia</topic><topic>Tobacco</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orhan, F.</creatorcontrib><creatorcontrib>Schwieler, L.</creatorcontrib><creatorcontrib>Fatouros‐Bergman, H.</creatorcontrib><creatorcontrib>Malmqvist, A.</creatorcontrib><creatorcontrib>Cervenka, S.</creatorcontrib><creatorcontrib>Collste, K.</creatorcontrib><creatorcontrib>Flyckt, L.</creatorcontrib><creatorcontrib>Farde, L.</creatorcontrib><creatorcontrib>Sellgren, C. M.</creatorcontrib><creatorcontrib>Piehl, F.</creatorcontrib><creatorcontrib>Engberg, G.</creatorcontrib><creatorcontrib>Erhardt, S.</creatorcontrib><creatorcontrib>Hedberg, Mikael</creatorcontrib><creatorcontrib>Victorsson, Pauliina</creatorcontrib><creatorcontrib>Karolinska Schizophrenia Project (KaSP) Consortium</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Uppsala universitet</collection><jtitle>Acta psychiatrica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orhan, F.</au><au>Schwieler, L.</au><au>Fatouros‐Bergman, H.</au><au>Malmqvist, A.</au><au>Cervenka, S.</au><au>Collste, K.</au><au>Flyckt, L.</au><au>Farde, L.</au><au>Sellgren, C. M.</au><au>Piehl, F.</au><au>Engberg, G.</au><au>Erhardt, S.</au><au>Hedberg, Mikael</au><au>Victorsson, Pauliina</au><aucorp>Karolinska Schizophrenia Project (KaSP) Consortium</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased number of monocytes and plasma levels of MCP‐1 and YKL‐40 in first‐episode psychosis</atitle><jtitle>Acta psychiatrica Scandinavica</jtitle><addtitle>Acta Psychiatr Scand</addtitle><date>2018-11</date><risdate>2018</risdate><volume>138</volume><issue>5</issue><spage>432</spage><epage>440</epage><pages>432-440</pages><issn>0001-690X</issn><issn>1600-0447</issn><eissn>1600-0447</eissn><abstract>Objective
Accumulating evidence implicates immune activation in the development of schizophrenia. Here, monocyte numbers, monocyte chemoattractant protein‐1 (MCP‐1) and chitinase‐3‐like protein 1 (YKL‐40) were investigated in plasma and cerebrospinal fluid (CSF) in first‐episode psychosis (FEP) patients.
Method
CSF and blood were sampled from 42 first‐episode psychosis (FEP) patients and 22 healthy controls. The levels of YKL‐40 and MCP‐1 were measured using electrochemiluminescence assay, and blood monocytes were counted using an XN‐9000‐hematology analyzer.
Results
We found higher plasma levels of MCP‐1 and YKL‐40 in FEP patients compared with healthy controls, a condition that was unrelated to antipsychotic and/or anxiolytic medication. This was combined with an increased number of blood monocytes and a borderline significant increase in YKL‐40 levels in the CSF of tobacco‐free FEP patients. Plasma or CSF chemokines or blood monocytes did not correlate with the severity of symptoms or the level of functioning.
Conclusion
These data demonstrate activation of monocytes in FEP and strengthens the idea of an immune dysfunction of psychotic disorders. Further studies are required to perceive a role of YKL‐40 and MCP‐1 in the initiation and progression of schizophrenia.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>30132802</pmid><doi>10.1111/acps.12944</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-1659-5232</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-690X |
| ispartof | Acta psychiatrica Scandinavica, 2018-11, Vol.138 (5), p.432-440 |
| issn | 0001-690X 1600-0447 1600-0447 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_486131 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Antipsychotics Blood Cell activation Cerebrospinal fluid Chemokines Chitinase first-episode psychosis Hematology Immune response Mental disorders Monocyte chemoattractant protein Monocytes neuroimmunology Plasma Plasma levels Psychosis Schizophrenia Tobacco |
| title | Increased number of monocytes and plasma levels of MCP‐1 and YKL‐40 in first‐episode psychosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T23%3A10%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20number%20of%20monocytes%20and%20plasma%20levels%20of%20MCP%E2%80%901%20and%20YKL%E2%80%9040%20in%20first%E2%80%90episode%20psychosis&rft.jtitle=Acta%20psychiatrica%20Scandinavica&rft.au=Orhan,%20F.&rft.aucorp=Karolinska%20Schizophrenia%20Project%20(KaSP)%20Consortium&rft.date=2018-11&rft.volume=138&rft.issue=5&rft.spage=432&rft.epage=440&rft.pages=432-440&rft.issn=0001-690X&rft.eissn=1600-0447&rft_id=info:doi/10.1111/acps.12944&rft_dat=%3Cproquest_swepu%3E2125490335%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2125490335&rft_id=info:pmid/30132802&rfr_iscdi=true |